CSBR
Price
$6.89
Change
+$0.39 (+6.00%)
Updated
Jun 6 closing price
Capitalization
95.27M
40 days until earnings call
MREO
Price
$2.74
Change
+$0.28 (+11.38%)
Updated
Jun 6 closing price
Capitalization
435.66M
122 days until earnings call
Interact to see
Advertisement

CSBR vs MREO

Header iconCSBR vs MREO Comparison
Open Charts CSBR vs MREOBanner chart's image
Champions Oncology
Price$6.89
Change+$0.39 (+6.00%)
Volume$11.54K
Capitalization95.27M
Mereo BioPharma Group
Price$2.74
Change+$0.28 (+11.38%)
Volume$2.19M
Capitalization435.66M
CSBR vs MREO Comparison Chart
Loading...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CSBR vs. MREO commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSBR is a StrongBuy and MREO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (CSBR: $6.89 vs. MREO: $2.74)
Brand notoriety: CSBR and MREO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSBR: 35% vs. MREO: 148%
Market capitalization -- CSBR: $95.27M vs. MREO: $435.66M
CSBR [@Biotechnology] is valued at $95.27M. MREO’s [@Biotechnology] market capitalization is $435.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSBR’s FA Score shows that 1 FA rating(s) are green whileMREO’s FA Score has 1 green FA rating(s).

  • CSBR’s FA Score: 1 green, 4 red.
  • MREO’s FA Score: 1 green, 4 red.
According to our system of comparison, CSBR is a better buy in the long-term than MREO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSBR’s TA Score shows that 4 TA indicator(s) are bullish while MREO’s TA Score has 5 bullish TA indicator(s).

  • CSBR’s TA Score: 4 bullish, 4 bearish.
  • MREO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MREO is a better buy in the short-term than CSBR.

Price Growth

CSBR (@Biotechnology) experienced а +17.38% price change this week, while MREO (@Biotechnology) price change was +27.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

CSBR is expected to report earnings on Sep 10, 2025.

MREO is expected to report earnings on Oct 07, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MREO($436M) has a higher market cap than CSBR($95.3M). CSBR YTD gains are higher at: -19.603 vs. MREO (-21.714). CSBR has higher annual earnings (EBITDA): 8.43M vs. MREO (-43.41M). MREO has more cash in the bank: 80.5M vs. CSBR (3.2M). CSBR (6.44M) and MREO (6.68M) have identical debt. CSBR has higher revenues than MREO: CSBR (58.6M) vs MREO (1M).
CSBRMREOCSBR / MREO
Capitalization95.3M436M22%
EBITDA8.43M-43.41M-19%
Gain YTD-19.603-21.71490%
P/E Ratio15.31N/A-
Revenue58.6M1M5,860%
Total Cash3.2M80.5M4%
Total Debt6.44M6.68M96%
FUNDAMENTALS RATINGS
CSBR vs MREO: Fundamental Ratings
CSBR
MREO
OUTLOOK RATING
1..100
1113
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
1095
PRICE GROWTH RATING
1..100
4762
P/E GROWTH RATING
1..100
832
SEASONALITY SCORE
1..100
9545

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (76) in the null industry is in the same range as CSBR (82) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

MREO's Profit vs Risk Rating (71) in the null industry is in the same range as CSBR (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

CSBR's SMR Rating (10) in the Biotechnology industry is significantly better than the same rating for MREO (95) in the null industry. This means that CSBR’s stock grew significantly faster than MREO’s over the last 12 months.

CSBR's Price Growth Rating (47) in the Biotechnology industry is in the same range as MREO (62) in the null industry. This means that CSBR’s stock grew similarly to MREO’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for CSBR (83) in the Biotechnology industry. This means that MREO’s stock grew significantly faster than CSBR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSBRMREO
RSI
ODDS (%)
Bullish Trend 1 day ago
69%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
81%
Bearish Trend 24 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRGGX40.99N/A
N/A
MFS Core Equity R1
PMDDX17.77N/A
N/A
Principal Small-MidCap Dividend Inc C
EILIX13.90N/A
N/A
Eaton Vance International Small-Cap I
SAHMX15.33N/A
N/A
SA International Value
VVICX9.68N/A
N/A
VOYA VACS Index Series SC Portfolio

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and SYRE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and SYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
+6.00%
SYRE - CSBR
32%
Poorly correlated
+2.11%
SCNI - CSBR
27%
Poorly correlated
-21.54%
OABI - CSBR
25%
Poorly correlated
+8.70%
MREO - CSBR
24%
Poorly correlated
+11.38%
PLUR - CSBR
24%
Poorly correlated
-0.61%
More

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with CRNX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
+11.38%
CRNX - MREO
49%
Loosely correlated
+2.13%
TRDA - MREO
47%
Loosely correlated
+2.46%
KYMR - MREO
44%
Loosely correlated
-0.08%
KOD - MREO
44%
Loosely correlated
+7.65%
IDYA - MREO
44%
Loosely correlated
+2.99%
More